THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • March 12th, 2020 • Nabriva Therapeutics PLC • Pharmaceutical preparations
Contract Type FiledMarch 12th, 2020 Company IndustryTHIS THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of March 11, 2020 (the “Third Amendment Signing Date”), is made among Nabriva Therapeutics Public Limited Company, a public limited company incorporated in Ireland under registration number 599588 and having its registered office at 25-28 North Wall Quay, IFSC, Dublin 1, Ireland (“Parent”), Nabriva Therapeutics Ireland Designated Activity Company, a designated activity company incorporated in Ireland under registration number 612454 and having its registered office at Alexandra House, Office 225/227, The Sweepstakes, Ballsbridge, Dublin 4, D04 C7H2, Republic of Ireland (“Nabriva Ireland”; together with Parent, individually and collectively, jointly and severally, the “Borrower”), Nabriva Therapeutics GmbH, a limited liability company (Gesellschaft mit beschränkter Haftung) incorporated under the laws of the Republic of Austria, having its seat in Vienna and its registered address at Leberstraße 20, 1110 Vi
SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • March 12th, 2020 • Nabriva Therapeutics PLC • Pharmaceutical preparations
Contract Type FiledMarch 12th, 2020 Company IndustryTHIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of January 8, 2020 (the “Amendment Effective Date”), is made among Nabriva Therapeutics Public Limited Company, a public limited company incorporated in Ireland under registration number 599588 and having its registered office at 25-28 North Wall Quay, Dublin 1, Ireland (“Parent”), Nabriva Therapeutics Ireland Designated Activity Company, a designated activity company incorporated in Ireland under registration number 612454 and having its registered office at Suite 510, Regus Dublin Airport, Skybridge House, Dublin Airport, Swords, County Dublin, Ireland (“Nabriva Ireland”; together with Parent, individually and collectively, jointly and severally, the “Borrower”), Nabriva Therapeutics GmbH, a limited liability company (Gesellschaft mit beschränkter Haftung) incorporated under the laws of the Republic of Austria, having its seat in Vienna and its registered address at Leberstraße 20, 1110 Vienna, and regi
NABRIVA THERAPEUTICS PLC SHARE OPTION / CASH-SETTLED SHARE APPRECIATION RIGHT AGREEMENT GRANTED UNDER 2020 SHARE INCENTIVE PLANShare Option / Cash-Settled Share Appreciation Right Agreement • March 12th, 2020 • Nabriva Therapeutics PLC • Pharmaceutical preparations • Dublin
Contract Type FiledMarch 12th, 2020 Company Industry JurisdictionThis Share Option /Cash-Settled Share Appreciation Right Agreement (this “Agreement”) is made between Nabriva Therapeutics plc, a public limited company organized under the laws of Ireland (the “Company”), and the Participant pursuant to the 2020 Share Incentive Plan (the “Plan”).
NABRIVA THERAPEUTICS PLC RESTRICTED SHARE UNIT AGREEMENT GRANTED UNDER 2017 SHARE INCENTIVE PLANRestricted Share Unit Agreement • March 12th, 2020 • Nabriva Therapeutics PLC • Pharmaceutical preparations • Delaware
Contract Type FiledMarch 12th, 2020 Company Industry JurisdictionThis Restricted Share Unit Agreement (this “Agreement”) is made between Nabriva Therapeutics plc, a public limited company organized under the laws of Ireland (the “Company”), and the Participant pursuant to the 2017 Share Incentive Plan (the “Plan”).